Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2005
08/04/2005WO2005070461A2 Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
08/04/2005WO2005070460A2 Combination therapy with 5-ht1a and 5-ht1b receptor antagonists
08/04/2005WO2005070443A1 Timber bark extract
08/04/2005WO2005070437A1 Drug for treating pain
08/04/2005WO2005070436A1 A composition containing ginsenoside f1 or compound k for skin external application
08/04/2005WO2005070435A1 Agent for improving dynamic eyesight
08/04/2005WO2005070434A2 Treatment of aromatase inhibitor therapy-related osteoporosis
08/04/2005WO2005070433A1 Use of pentoxifylline for the prevention or treatment of ulcers
08/04/2005WO2005070432A1 Use of pdgf-r tk inhibitors for the treatment of myocarditis and its complications
08/04/2005WO2005070431A1 Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
08/04/2005WO2005070429A1 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
08/04/2005WO2005070428A1 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
08/04/2005WO2005070427A1 Compounds for the sustained reduction of body weight
08/04/2005WO2005070426A1 Freeze-dried (-)-pantoprazole preparation and (-)-pantoprazole injection
08/04/2005WO2005070425A1 Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
08/04/2005WO2005070424A1 Methods of using zonisamide as an adjunctive therapy for partial seizures
08/04/2005WO2005070423A1 Methods of using zonisamide as an adjunctive therapy for partial seizures
08/04/2005WO2005070422A1 Methods of using zonisamide as an adjunctive therapy for partial seizures
08/04/2005WO2005070421A1 Fluconazole-tinidazole combination for the treatment of vaginal infections, composition thereof and preparation and use of same
08/04/2005WO2005070420A1 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
08/04/2005WO2005070419A1 Chemical inhibitors of soluble adenylyl cyclase (sac)
08/04/2005WO2005070418A1 Immunomodulatory alkaloids
08/04/2005WO2005070417A1 Compression coated tablet comprising sumatriptan
08/04/2005WO2005070416A1 Indirubin derivatives having anticancer property against human cancer cell me
08/04/2005WO2005070415A1 Adjuvant compositions
08/04/2005WO2005070414A1 Conformationally constrained paclitaxel analogs and their use as anticancer and anti-alzheimers agents
08/04/2005WO2005070413A1 Retinoic acid-containing remedy for diabetes
08/04/2005WO2005070412A2 Method of using punicic acid to enhance immune response and prevent metabolic disorders
08/04/2005WO2005070411A1 USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES
08/04/2005WO2005070410A1 Method of treating type iii hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
08/04/2005WO2005070409A1 A method of modulating pro-inflammatory and inflammatory activity mediated by c-reactive protein
08/04/2005WO2005070408A1 Stress relieving composition
08/04/2005WO2005070407A1 Methods of treatment of amyloidosis using aspartyl-protease inihibitors
08/04/2005WO2005070406A1 Combination of organic compounds
08/04/2005WO2005070405A1 Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
08/04/2005WO2005070404A1 Ceramide formulations suitable for oral administration
08/04/2005WO2005070403A1 Anti-estrogens and methods of use
08/04/2005WO2005070402A1 Method and composition for treating acne using lignan compounds
08/04/2005WO2005070399A1 Microemulsions for pharmaceutical compositions
08/04/2005WO2005070398A2 Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
08/04/2005WO2005070397A1 Method of preparing low-crystallinity oltipraz or amorphous oltipraz
08/04/2005WO2005070396A1 Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them
08/04/2005WO2005070393A2 Directly compressible pharmaceutical composition of the rapamycin ester cci-779
08/04/2005WO2005070392A2 Non-lamellar compositions of dioleoyl phosphatidylethanolamine and polysorbate 80
08/04/2005WO2005070390A2 Mitratapide oral solution
08/04/2005WO2005070207A1 Modulators of the glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof
08/04/2005WO2005070133A2 2,6-disubstituted piperidines as modulators of chemokine receptor activity
08/04/2005WO2005070113A2 9n-substituted 6-11 bicyclic erythromycin derivatives
08/04/2005WO2005070081A2 Methods of using zonisamide as an adjunctive therapy for partial seizures
08/04/2005WO2005070080A2 Methods of using zonisamide as an adjunctive therapy for partial seizures
08/04/2005WO2005070079A2 Methods of using zonisamide as an adjunctive therapy for partial seizures
08/04/2005WO2005070078A2 Methods of using zonisamide as an adjunctive therapy for partial seizures
08/04/2005WO2005070077A2 Methods of using zonisamide as an adjunctive therapy for partial seizures
08/04/2005WO2005070072A2 Reciprocal regulation of inflammation and lipid metabolism by liver x receptors
08/04/2005WO2005070058A2 Methods and compositions for facilitating metabolic control
08/04/2005WO2005070052A2 Use of photodynamic therapy to enhance treatment with immuno-modulating agents
08/04/2005WO2005070043A2 Methods for treating non-melanoma cancers with paba
08/04/2005WO2005070042A2 Novel chemical compounds
08/04/2005WO2005070024A2 Treatment of cancer using benzoic acid derivatives
08/04/2005WO2005070008A2 Polymer no donor predrug nanofiber coating for medical devices and therapy
08/04/2005WO2005070006A2 Nitrosated and/or nitrosylated compounds, compositions and methods of use
08/04/2005WO2005070003A2 Abuse potential reduction in abusable substance dosage form
08/04/2005WO2005069982A2 Wound treatment composition and process of manufacture
08/04/2005WO2005069933A2 Methods of treating an inflammatory-related disease
08/04/2005WO2005069906A2 Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
08/04/2005WO2005069894A2 Conformationally constrained smac mimetics and the uses thereof
08/04/2005WO2005069880A2 Modulation of line-1 reverse transcriptase
08/04/2005WO2005069865A2 Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
08/04/2005WO2005069855A2 Modulators of angiogenesis
08/04/2005WO2005069771A2 Small molecule antagonists of bcl-2 family proteins
08/04/2005WO2005069758A2 Frequency assisted transdermal agent delivery method and system
08/04/2005WO2005069731A2 Method for treating oral aphthous stomatitis and oral mucositis
08/04/2005WO2005060978A3 Polymetaphosphate based formulations for therapy of microcrystalline arthropathies
08/04/2005WO2005060661A3 METHODS AND MATERIALs FOR ASSESSING PROSTATE CANCER THERAPIES
08/04/2005WO2005060330A3 Freeze-dried vaccine adjuvant
08/04/2005WO2005058976A3 Low molecular polysaccharides having antithrombotic activity
08/04/2005WO2005058819A3 Polymorphic forms of tegaserod base and salts thereof
08/04/2005WO2005058245A3 Synthetic process
08/04/2005WO2005054244A3 Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
08/04/2005WO2005053710A3 Food composition comprising glucosamine
08/04/2005WO2005053652A8 Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
08/04/2005WO2005053605A3 Therapeutic liposomes
08/04/2005WO2005051917B1 Pyrazolyl derivatives in the form of drugs for treating acute or chronic neuronal regressions
08/04/2005WO2005048956A3 Estradiol-related compounds and methods of use as anti-tumor agents
08/04/2005WO2005048930A3 Surfactant-based gel as an injectable, sustained drug delivery vehicle
08/04/2005WO2005046677A3 At1-receptor antagonists for treating nephrotic syndrome
08/04/2005WO2005046666A8 Pharmaceutical composition for treating stress incontinence and/or mixed incontinence
08/04/2005WO2005042022A3 Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
08/04/2005WO2005041853A3 Antibacterial and/or antiprotozoal nitroimidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines.
08/04/2005WO2005040355A3 Tao kinase modulators and methods of use
08/04/2005WO2005039319A3 Synbiotic composition for infants
08/04/2005WO2005037259A3 Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
08/04/2005WO2005037216A3 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
08/04/2005WO2005037206A3 Anti-cancer compounds and methods of use thereof
08/04/2005WO2005034929A3 Tissue remodeling and vascularization
08/04/2005WO2005034919B1 Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
08/04/2005WO2005033048A3 Wnt pathway antagonists
08/04/2005WO2005032527A3 Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy
08/04/2005WO2005032464A3 Phenyl pyrrolidine ether tachykinin receptor antagonists
08/04/2005WO2005030188A3 Phenyl-piperazine derivatives as modulators of muscarinic receptors
1 ... 4589 4590 4591 4592 4593 4594 4595 4596 4597 4598 4599 4600 4601 4602 4603 4604 4605 4606 4607 4608 4609 ... 7860